{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:09:27Z","timestamp":1740164967716,"version":"3.37.3"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.msard.2023.105048","type":"journal-article","created":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T18:14:40Z","timestamp":1696961680000},"page":"105048","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Lessons learned after 20 years of real-world experience with natalizumab"],"prefix":"10.1016","volume":"80","author":[{"given":"Bhupendra O.","family":"Khatri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tayo","family":"Olapo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Beals","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Lindman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toni","family":"Perea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Van Zealand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan R","family":"Metzger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2023.105048_bib0009","unstructured":"Avila R., Adams B., Stevenson J., et\u00a0al. PML incidence rates in US patients treated with natalizumab: Update from the TOUCH\u00aeprogram. Presented at: Americas Committee For Treatment and Research in Multiple Sclerosis Forum; 2022; West Palm Beach, FL, USA."},{"key":"10.1016\/j.msard.2023.105048_bib0010","unstructured":"Biogen, 2023. Tysabri Prescribing Information. https:\/\/www.tysabri.com\/content\/dam\/commercial\/tysabri\/pat\/en_us\/pdf\/tysabri_prescribing_information.pdf."},{"issue":"20","key":"10.1016\/j.msard.2023.105048_bib0001","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.msard.2023.105048_bib0013","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/1756285614540224","article-title":"Extended interval dosing of natalizumab: a two-center, 7-year experience","volume":"7","author":"Bomprezzi","year":"2014","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"6","key":"10.1016\/j.msard.2023.105048_bib0011","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1007\/s13365-016-0482-z","article-title":"Statistical analysis of PML incidences of natalizumab-treated patients from 2009 to 2016: outcomes after introduction of the Stratify JCV(R) DxSelect antibody assay","volume":"22","author":"Campagnolo","year":"2016","journal-title":"J. Neurovirol."},{"issue":"12","key":"10.1016\/j.msard.2023.105048_bib0012","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1136\/jnnp-2020-323472","article-title":"Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis","volume":"91","author":"Chisari","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2023.105048_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.117385","article-title":"MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study","volume":"424","author":"De Mercanti","year":"2021","journal-title":"J. Neurol. Sci."},{"issue":"7","key":"10.1016\/j.msard.2023.105048_bib0018","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S1474-4422(22)00143-0","article-title":"Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial","volume":"21","author":"Foley","year":"2022","journal-title":"Lancet Neurol."},{"issue":"11","key":"10.1016\/j.msard.2023.105048_bib0003","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies","volume":"16","author":"Ho","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2023.105048_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102842","article-title":"Reduction of the risk of PML in natalizumab treated MS patients in Sweden: an effect of improved PML risk surveillance","volume":"50","author":"K\u00e5gstr\u00f6m","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2023.105048_bib0006","first-page":"117","article-title":"Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group","volume":"87","author":"McGuigan","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2023.105048_bib0002","doi-asserted-by":"crossref","DOI":"10.1002\/ana.24286","article-title":"Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","author":"Plavina","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2023.105048_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.614715","article-title":"Does extended interval dosing natalizumab preserve effectiveness in multiple sclerosis? A 7 year-retrospective observational study","volume":"12","author":"Riancho","year":"2021","journal-title":"Front. Immunol."},{"issue":"15","key":"10.1016\/j.msard.2023.105048_bib0005","doi-asserted-by":"crossref","first-page":"e1452","DOI":"10.1212\/WNL.0000000000008243","article-title":"Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing","volume":"93","author":"Ryerson","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.105048_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103480","article-title":"No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: real-world evidence from MS PATHS","volume":"58","author":"Ryerson","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"10.1016\/j.msard.2023.105048_bib0015","doi-asserted-by":"crossref","first-page":"e745","DOI":"10.1212\/WNL.0000000000009995","article-title":"Personalized extended interval dosing of natalizumab in MS: a prospective multicenter trial","volume":"95","author":"van Kempen","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2023.105048_bib0008","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/jamaneurol.2019.2670","article-title":"Progressive multifocal leukoencephalopathy incidence and risk stratification among natalizumab users in France","volume":"77","author":"Vukusic","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2023.105048_bib0014","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.msard.2018.06.015","article-title":"Efficacy and safety of natalizumab extended interval dosing","volume":"24","author":"Yamout","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"8","key":"10.1016\/j.msard.2023.105048_bib0004","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1136\/jnnp-2015-312940","article-title":"Extended interval dosing of natalizumab in multiple sclerosis","volume":"87","author":"Zhovtis Ryerson","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823005497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823005497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T01:21:29Z","timestamp":1724894489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823005497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":19,"alternative-id":["S2211034823005497"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.105048","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lessons learned after 20 years of real-world experience with natalizumab","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.105048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105048"}}